Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S.

New Post Public Reply Private Reply Replies (1) Message Board

Feb 22, 2012 at 12:11 PM

Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) critical ailment formulations, is excited to announce the appointment of world renowned Cannabis Cultivator Bret Bogue as Director of Horticulture for the company. Mr. Bogue is a valuable addition to the company, with decades of experience growing cannabis for medical purposes.

Mr. Bogue will play a key role in the development and maintenance of all horticulture operations for the company while developing specific strains for mass production for the company’s growing standards and critical ailment formulations developed by the company. Mr. Bogue will be a part of the lead development team for plants and strains to be used to develop these medical cannabis formulations and products for Cannabis Science.

Being a critical cancer patient himself, Mr. Bogue was diagnosed with a very rare form of melanoma in 1995. Mr. Bogue stated, "I became very ill and was looking for an alternative medication for my illness, so I realized then that I needed to create Apothecary™ Genetics to provide an alternative treatment solution in the early 90s. Through my world travels, I have been able to find ‘land race strains’ and breed them with hybrids to create World Class medical cannabis.”

Bret and Apothecary went on to become the first American-based seed company to win the coveted Cannabis Cup in Amsterdam in 2007, and has won many other international and national awards for his medical cannabis developments. Having over 20 years of experience creating unique medical strains of cannabis, such as Grape Ape aka GDP, Kaia Kush, Sour Grapes, Old School Jams, and Goo, just to name a few, has put Bret and Apothecary Genetics on the world map as one of the top leaders in medical cannabis development.

Mr. Bogue concludes with, “ I was able to cure my melanoma by using medical cannabis in combination with standard radiation treatment. I am the living proof that medical cannabis kills cancer cells.”

As well, Bret is embarking on some exciting new projects such as a documentary with television giant A&E. Two pilots have already been filmed and sent to New York for review and approvals. The documentary will show real patients who are having real, positive results with medical cannabis. These patients include seniors from a senior citizens’ community in California. Viewers will see the reality of the medication’s benefits, as well as the emotions that come into play when someone is chronically ill.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

http://www.cannabisscience.com/

Cannabis Science Inc (CBIS) Stock Research Links

CBIS Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Medicare Competitive Bidding May Slash Jobs, Access

Medicare's New Program: Potential Knockout Punch? Today, we dive into Medicare's latest shake-up that might just be the unseen wrecking ball swinging toward thousands of jobs and small businesses in the healthcare sector. Two years from now, starting January 2028, the Competitive Bidding Program is set to reroute the entire landscape for suppliers of key medical products...

Red Banyan Earns Top Honors in Florida for 2026

Red Banyan: A Powerhouse in Reputation Management Boy, have you ever watched a company rise through the ranks almost like a caffeine kick on a drowsy morning? That's Red Banyan for you. This outfit, right out of Fort Lauderdale, snagged the '2026 Best of Florida' award as the cream of the crop in the Business Consulting Firms category. It’s like taking home an Oscar in...

ScholarShare 529 Launches $50 Back-to-School Promo

California Families Get a Boost With New 529 Plan Offer Everywhere you turn, it's 'back to school' mania right now, and ScholarShare 529 aims to ride that wave by sweetening the pot for parents ready to think ahead. So here's the gist—California's official college savings plan is handing out a $50 gift card for new accounts opened between now and September 30th. Setting...

Jacob Walthour to Be Honored for Economic Leadership

The Honoring of Leadership That Goes Beyond Business In a world where financial influence often feels like it funnels into the same familiar pockets, the news of Jacob Walthour Jr.'s upcoming recognition feels like a fresh breeze of change. The Alpha Phi Alpha's Alpha Alpha Lambda Chapter is rolling out the red carpet at its Centennial Gala for Walthour, throwing him into...

American Savings Bank IPO Hits NYSE: $129M Raised

A Big Day for American Savings Bank Buckled up yet? Because American Savings Bank has just shot onto the NYSE, raising a hefty $129 million. A solid start, I’d say, for a Honolulu-based outfit that now struts around with a valuation tipping beyond $1.03 billion. That’s what you get when you price more than eight million shares at $16 a pop. NYSE:ASBH is the new kid on...

Koogler's Sale to ALL4: A Game-Changer for the Southeast

A Strategic Alignment Unfolds in Environmental Engineering Ever notice how those industry shifts often sneak up on you, only to leave a mark that's hard to ignore? That's exactly what's playing out with Koogler & Associates' recent hookup with ALL4 LLC. Set aside that coffee, this one's too important to miss if you've got a stake in the environmental consulting game or...

B2B Growth Hinges on Narrative Coherence, Study Shows

Clear Stories, Stronger Growth If companies can't tell a clear story that their buyers understand and believe, they're destined to stagnate. That's the blunt reality kompeld is pushing with their H2 2026 Narrative Coherence Benchmark. The report scores 150 B2B tech companies on their narrative coherence, showing there's a stark correlation between storytelling and growth....

Ransoms and Mega-Losses Surge in Cyber Claims Study

Cyber Costs Skyrocket in Latest Study NetDiligence’s 2026 Cyber Claims Study isn't just another report—it’s a wake-up call. The numbers paint a stark picture: cyber incidents are burning deeper holes in pockets, and no one's immune. Whether you're a scrappy SME or a lumbering corporate giant, this report puts a magnifying glass to the chilling reality of cyber...

Finastra Recognized as 2026 Leader in Payment Platforms

Finastra Steals the Spotlight in Payments Innovation When it comes to the modern world of finance, nothing screams ‘adapt or fade into oblivion’ like the payments industry. Well, here’s a reality check from QKS Group: Finastra has snatched the spotlight in their SPARK Matrix™ for 2026 as a powerhouse in integrated bank payments platforms. Clearly, this ain’t...

Propensity Rockets to No. 70 on the 2026 Inc. 5000 List

Hold onto your hats, folks—Propensity just blasted its way to Number 70 on the Inc. 5000 for 2026. That's quite a leap from the 2,591 spot just last year. If you're scratching your head wondering what's behind this meteoric rise, it’s all about AI and knowing which buyer signals really matter. The AI Advantage in B2B The B2B marketing space isn't exactly the new Wild...